Navigation Links
High EGFR expression a predictor for improved survival with cetuximab plus chemotherapy
Date:7/5/2011

High epidermal growth factor receptor (EGFR) expression was a good predictor of which lung cancer patients would survive longer when cetuximab (Erbitux) was added to first-line chemotherapy, according to research presented at the 14th World Conference on Lung Cancer in Amsterdam, hosted by the International Association for the Study of Lung Cancer (IASLC).

"The new analysis of the Phase III FLEX study has allowed us to identify which non-small cell lung cancer patients are most likely to benefit from treatment with Erbitux in the first-line setting," said principal investigator Dr. Robert Pirker of the Medical University of Vienna in Austria. "By demonstrating that high EGFR expression is the first predictive biomarker for improved overall survival in advanced NSCLC, we have taken a major step towards a more personalized approach in this difficult-to-treat disease."

Based on a new analysis of all FLEX patients (1,121 out of 1,125 FLEX study patients), researchers found that patients with high tumor EGFR expression (200 and above on a scale of 0-300) consistently benefited from the addition of cetuximab to chemotherapy regardless of histology. Within this group, overall survival averaged 12 months, compared with 9.6 months for patients receiving chemotherapy alone.

In patients with low EGFR expression, no difference in overall survival was seen between patients receiving chemotherapy plus cetuximab, compared to those receiving chemotherapy alone.


'/>"/>

Contact: Renee McGaw
renee.mcgaw@ucdenver.edu
31-205-493-413
International Association for the Study of Lung Cancer
Source:Eurekalert

Page: 1

Related medicine news :

1. Gene expression changes in nasal cells may help identify lung cancer in earliest stages
2. Smokers undergo the same changes in gene expression as patients with COPD
3. Gene expression predicts chemotherapy sensitivity of triple-negative breast cancer
4. RxPONDER trial will evaluate whether gene expression test can drive chemotherapy choice
5. Low doses of penta-brominated diphenyl ether flame retardants alter gene expression
6. Novel mechanism for control of gene expression revealed
7. New study finds molecular mechanisms that control Rb2/p130 gene expression in lung cancer
8. Gene expression to distinguish metastasizing from non-metastasizing head and neck cancers
9. Oncometabolite linked with widespread alterations in gene expression
10. Overexpression of repetitive DNA sequences discovered in common tumor cells
11. Attention ladies and gentlemen: Courtship affects gene expression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... San Diego, CA (PRWEB) , ... March 28, 2017 , ... ... and turtlenecks from the daily wardrobe. However, for those self-conscious about a double chin, ... believe they have the ideal solution. , “For most people, a double chin ...
(Date:3/28/2017)... ... March 28, 2017 , ... Neurotechnology , ... biometric time and attendance tracking products: the new NCheck Cloud Bio Attendance cloud-based ... Attendance uses biometric face recognition to enable users to check in and out ...
(Date:3/28/2017)... ... March 28, 2017 , ... Columbus OH. Dr. Justin ... one of few medical professionals in the country to sit on the 2017 National ... Aesthetics, in just 2 years Dr. Harper helped propel the clinic from a small ...
(Date:3/28/2017)... Atlantic City, NJ (PRWEB) , ... March 28, ... ... annual American Camp Association’s Tri-State Camp Conference in Atlantic City March 13-16, was ... partners, and their team of professional staff discussed strategies for preventing outbreaks among ...
(Date:3/28/2017)... St. Louis, MO (PRWEB) , ... March 28, ... ... high levels of job satisfaction in their profession as their value increases in ... a company that provides resources such as job boards, career fairs, and candidate ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... United Kingdom and  BOSTON , March 28, ... Linguamatics today announced a partnership with ... The agreement allows pharmaceutical companies to extract key ... I2E text mining technology. The ... of the top 20 global pharmaceutical companies. The ...
(Date:3/28/2017)... , March 28, 2017  AcelRx Pharmaceuticals, Inc. ... the development and commercialization of innovative therapies for ... the European Medicines Agency (EMA) has notified the ... mcg) Marketing Authorisation Application (MAA) has passed validation, ... is underway. The MAA for ARX-04 (known as ...
(Date:3/28/2017)... 28, 2017 The global ... 8.0 billion by 2025, according to a new study ... infectious diseases and cancer is expected to upsurge the ... over the coming years. In addition, higher number of ... allogenic stem cell therapy, due to adverse effects caused ...
Breaking Medicine Technology: